Annamycin + Ara-C (Cytarabine)

June 04, 2026 — Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that CEO Walter Klemp participated in a Virtual Investor “What This Means” segment focused on the company’s AML program. Klemp highlighted a key operational milestone: enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial (MB-108), evaluating Annamycin plus cytarabine (AnnAraC) in adults with relapsed or refractory acute myeloid leukemia (R/R AML).

The company said reaching 45 enrolled subjects triggers the final preparation phase for an interim analysis, with unblinding of the 45-subject dataset still targeted for mid-2026. Moleculin characterized this interim readout as a potentially defining inflection point for the company.

Business/clinical significance: enrollment progress keeps the pivotal program on schedule toward a near-term interim efficacy/safety assessment that could meaningfully influence development and potential regulatory strategy for Annamycin in R/R AML (subject to financing and regulatory feedback).